Jason Barker has been appointed as Vice President - Finance of the Company effective 8/1/2020.He is a finance executive with over 25 years of experience that includes building and leading corporate finance, treasury and accounting functions within public and private companies, joined Arcus in May 2019. His experience encompasses work with start-ups, mid-cap and Fortune 500 companies operating primarily in the areas of life science and technology. Prior to joining Arcus, Mr. Barker was at Audentes Therapeutics from February 2015 to May 2019, most recently serving as Vice President of Finance. At Audentes, Mr. Barker was responsible for finance, accounting, tax, treasury, external reporting, risk management and oversight of certain legal functions. During his time at Audentes, Mr. Barker led the company’s operational readiness leading up to and following successful completion of its IPO in 2016 and also served as CFO for the company’s international subsidiaries. Prior to Audentes, Mr. Barker served as Managing Director at Bauer York LLC, providing finance consulting services to businesses within Silicon Valley. During his tenure at Bauer York, Mr. Barker served as interim CFO for Zosano Pharma during their preparations for an IPO. From 2004-2011, Mr. Barker held several positions of increasing responsibility at ARYx Therapeutics including serving as Head of Finance and Principal Accounting Officer while contributing to the company’s successful IPO in 2007. Mr. Barker earned a B.A. in Finance, Accounting, and Business Law, with honors, from the University of Texas at Arlington.
Jason Barker is 50, he's been the Vice President - Finance of Arcus Biosciences Inc since 2020. There are 10 older and 3 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
Jason's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead, and Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: